Vaxart, Inc Appoints James F. Cummings as Chief Medical Officer
September 27, 2021 at 08:00 am
Share
Vaxart, Inc. announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development. He joins Vaxart as the Company prepares to begin its Phase II clinical trials for COVID-19 with an oral tablet formulation. Dr. Cummings brings a 26-year career in the U.S. Army serving as Director of the Department of Defense's Global Emerging Infectious Surveillance and Response System (GEIS), with Biosurveillance Laboratories in 71 countries, Director of Translational Medicine & Regulated Activities for the Walter Reed Army Institute of Research (WRAIR), and Consultant to the Surgeon General for all medical research and development. Before joining Vaxart, Dr. Cummings served as President, Government and Public Health Solutions at Icon GPHS, the federal business unit of Icon PLC, a leading global Contract Research Organization (CRO), and Vice President of Clinical Development and Translational Medicine at Novavax. He joined Vaxart earlier this month.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.